Genetically modified organisms and visceral leishmaniasis

Chhajer, Rudra ; Ali, Nahid (2014) Genetically modified organisms and visceral leishmaniasis Frontiers in Immunology, 5 . Article ID 213-10 pages. ISSN 1664-3224

PDF - Publisher Version

Official URL:

Related URL:


Vaccination is the most effective method of preventing infectious diseases. Since the eradication of small pox in 1976, many other potentially life compromising if not threatening diseases have been dealt with subsequently. This event was a major leap not only in the scientific world already burdened with many diseases but also in the mindset of the common man who became more receptive to novel treatment options. Among the many protozoan diseases, the leishmaniases have emerged as one of the largest parasite killers of the world, second only to malaria. There are three types of leishmaniasis namely cutaneous (CL), mucocutaneous (ML), and visceral (VL), caused by a group of more than 20 species of Leishmania parasites. Visceral leishmaniasis, also known as kala-azar is the most severe form and almost fatal if untreated. Since the first attempts at leishmanization, we have killed parasite vaccines, subunit protein, or DNA vaccines, and now we have live recombinant carrier vaccines and live attenuated parasite vaccines under various stages of development. Although some research has shown promising results, many more potential genes need to be evaluated as live attenuated vaccine candidates. This mini-review attempts to summarize the success and failures of genetically modified organisms used in vaccination against some of major parasitic diseases for their application in leishmaniasis.

Item Type:Article
Source:Copyright of this article belongs to Frontiers.
Keywords:Leishmania; Genetically Modified Parasites; Immunology; Vaccines; Visceral Leishmaniasis
ID Code:99470
Deposited On:28 Oct 2016 06:16
Last Modified:28 Oct 2016 06:16

Repository Staff Only: item control page